When available, the Online Course format is included with the hard copy, eBook, or audio book formats!
Release Date: September 30, 2016
Expiration Date: September 30, 2018
New VIDEO course format.
Led by Dr. Kathryn Blake at the Association of Asthma Educators Conference in August of 2016, this presentation keeps respiratory therapists and other health care professionals working with asthmatic patients on the cutting-edge of research by explaining the current controversies in asthma care. Stepping down therapy in well-controlled patients on ICS + LABA; using the new anti-IL-5 biologics (mepolizumab and reslizumab); the role of proton pump inhibitors; treating acute, non-chronic cough associated with upper respiratory infections are covered.
AARC Approval #147419000
This course is the result of a creative partnership between the Association of Asthma Educators and Western Schools. This presentation took place on August 6, 2016, at the Association of Asthma Educators 2016 Annual Conference in Jacksonville, Florida.
Video Production: Ed Roy Media (Jacksonville, Florida)
- Differentiate between the Global Initiative for Asthma Guidelines and FDA Safety Report with regard to recommendations for stepping down therapy in patients treated with inhaled corticosteroids plus long-acting beta agonist therapy.
- State the controversy surrounding FDA approval of mepolizumab and reslizumab for adolescents with severe persistent asthma.
- Describe the risks associated with codeine use for acute cough.
Kathryn Blake, PharmD, is director and principal research scientist, Nemours Center for Pharmacogenomics and Translational Research. She received her doctor of pharmacy degree from the University of Florida. In 2006, Dr. Blake received a 5-year K23 mentored training award from the National Heart, Lung, and Blood Institute for her project “Pharmacogenetics of Beta2-Agonists in Asthma.” In 2012, she was awarded a 4-year $2 million NIH R01 grant for her project “Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial.” She is a co-investigator on the Asthma Clinical Research Center network grant from the American Lung Association and on AsthmaNet, a nationwide clinical research network created by the National Heart, Lung, and Blood Institute in 2009. Her research interests are the pharmacogenomics of asthma drug therapy, racial differences in response to asthma drugs, technology use in research and health, and the effect of asthma and treatments in children with sickle cell disease. She serves on the U.S. Food and Drug Administration Pulmonary and Allergy Drugs Advisory Committee, and she represents the American Society of Health-System Pharmacists on the National Asthma Education and Prevention Program Coordinating Committee. Dr. Blake has been principal investigator on over 73 clinical studies in the areas of asthma, allergy, and cystic fibrosis and co-investigator on an additional 34. She has authored or co-authored more than 80 peer-reviewed publications and seven book chapters.
- Contact hours will be awarded for up to one (1) year from the date the course is ordered, unless otherwise indicated with an expiration date.
- You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
- Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
- All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
- The presenter of this continuing education activity has disclosed that she has received funding from GlaxoSmithKline, Boehringer Ingelheim, Merck & Co., PARI Respiratory Equipment, and TEVA Pharmaceuticals USA in support of network trials for Consortium PI for AsthmaNet and the American Lung Association Airways Clinical Research Centers. Funding has also been received from NIH and Novartis in the past 3 years. The peer reviewer has confirmed this presentation is current, evidence-based practice, and without bias.